LICENSE AGREEMENTLicense Agreement • December 11th, 2018 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
HMGU is a public research institution operating in the field of environmental health. Researchers at HMGU identified the endonuclease “Clo51” from the bacterial strain […***…] as an enzyme that can be used for genome editing purposes (hereinafter referred to as the “ORIGINAL MATERIAL”) as described in Annex 1. The technology involving the ORIGINAL MATERIAL is protected by the […***…].
